Drug intelligence / Profile preview

Chaiqin Ningshen granules

Development stage: Unknown
Lead developer: Shanxi Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Chaiqin Ningshen granules (ZY-B007) is a Traditional Chinese Medicine (TCM) botanical product developed by the Shanxi Institute of Traditional Chinese Medicine (Shanxi Provincial Hospital of TCM). It is formulated to treat insomnia disorder accompanied by anxiety symptoms, specifically targeting the TCM pattern of 'liver fire disturbing the spirit' (肝火扰神证). The name suggests the inclusion of *Bupleurum* (Chaihu) and *Scutellaria* (Huangqin), herbs traditionally used to clear heat and regulate liver function. The drug is currently undergoing Phase 2 clinical evaluation in China to determine its efficacy and safety in improving sleep parameters and reducing anxiety.

Other names: Chai Qin Ning Shen Ke Li柴芩宁神颗粒

Beyond the preview

Go deeper on Chaiqin Ningshen granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chaiqin Ningshen granules.

Explore the full profile